套细胞淋巴瘤（MCL）的新一代疗法：CAR-T细胞治疗后复发/难治性疾病治疗格局的演变
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells.
作者信息
Boccellato Elia, Comba Lorenzo, Tavarozzi Rita, Castellino Claudia, Foglietta Myriam, Mattei Daniele, Ladetto Marco, Massaia Massimo, Castellino Alessia
机构信息
Division of Hematology, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy.
Transfusion Medicine and Blood Establishment, Santa Croce e Carle Hospital, via Michele Coppino 26, 12100 Cuneo, Italy.
出版信息
Cancers (Basel). 2025 Jul 3;17(13):2239. doi: 10.3390/cancers17132239.
Abstract
Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...].
摘要
套细胞淋巴瘤（MCL）是一种罕见但异质性的非霍奇金淋巴瘤（NHL）亚型，其预后范围从惰性病例的非常良好到更具侵袭性变体的不良预后[……]。
Zotero 插件